PharmaTelevision - Paul Capital Partners: Growth Capital Providers for the Biotech Industry

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Paul Capital Partners: Growth Capital Providers for the Biotech Industry

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this interview, filmed during the recent BIO conference in San Diego, Fintan Walton speaks with Ken Macleod, partner in the well-known Paul Capital Partners, located in London. He tells how the company differs from traditional venture capitalist funds by providing funding based on royalty interests and revenue interests. Using these methods, Paul Capital is able to provide non-dilutive funding to companies that are looking to grow their operations in a variety of ways—providing cash for products in the pipeline, expanding their sales force, or launching new products. Their investments focus on companies that are already producing revenue or have products that are close to producing revenue, and their risk sharing model involves taking commercial risks rather than clinical or regulatory risks. Last year, financing of this kind provided over $2 billion in funds to the biotech and pharma industry and Paul Capital believes this number will continue to grow as companies look to use the potential of their royalty and revenue streams in ever more flexible ways.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The origins of the company and how the company differs from traditional venture capitalist funds by providing funding based on royalty interests and revenue interests.

Fintan Walton:

Hello and welcome to PharmaVentures business review here in San Diego, California. On this show I have Ken Macleod, who is a Partner of Paul Capital Partners based in the UK. Welcome to the show.

Ken Macleod:

Thank you very much.

Fintan Walton:

Ken Macleod, Paul Capital Partners is a reasonably well known organization"

Ken Macleod:

Yeah.

Fintan Walton:

Involved in royalty financing, could you tell us a little bit about the origins of Paul Capital Partners?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Ken Macleod

Partner

Ken Macleod, Ph.D. joined Paul Capital Partners in 2004 and is responsible for sourcing, evaluating and negotiating European and Asian investment opportunities for Paul Capital Healthcare. Based in London, Dr. Ken Macleod previously held senior management positions over a 15-year career at Serono, Abbott Laboratories, and Beecham Pharmaceuticals. Prior to joining Paul Capital Partners, Dr. Ken Macleod was a Venture Partner at Schroder Ventures Life Sciences where he was responsible for deal sourcing, evaluation, and negotiation of pharmaceutical investment opportunities. Dr. Ken Macleod earned his Ph.D. from the University of York, UK and his B.Sc. with honors in Biology from the University of Manchester, UK.

Paul Capital Partners

Paul Capital Partners established Paul Capital Healthcare in 1999 to meet the financing needs of healthcare companies, institutions and inventors. Today, the firm manages one of the largest dedicated healthcare funds globally with a total of $1.4 billion in assets under management. The Fund focuses on commercial stage healthcare products and investment opportunities in North America, Europe, and Asia. To date Paul Capital Healthcare has closed more than 30 investments in the pharmaceutical, biotechnology, medical device, and diagnostics areas. Public and private companies, research institutions and universities, and individual inventors have all benefited from the flexibility of Paul Capital Healthcare's investment approach. This capital has enabled them to transfer product risk, finance clinical and commercial development projects, acquire new products, fund university programs and capital needs, avoid conflicts of interest, unlock shareholder value, and monetize product royalties.